Compare BBY & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | JAZZ |
|---|---|---|
| Founded | 1966 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.4B |
| IPO Year | 1994 | 2007 |
| Metric | BBY | JAZZ |
|---|---|---|
| Price | $57.46 | $210.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 14 |
| Target Price | $76.28 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 3.0M | 814.8K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.54% | N/A |
| EPS Growth | ★ 17.76 | N/A |
| EPS | ★ 5.04 | N/A |
| Revenue | ★ $41,691,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $1.15 | $6.22 |
| Revenue Next Year | $1.38 | $7.68 |
| P/E Ratio | $11.44 | ★ N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $57.52 | $105.00 |
| 52 Week High | $84.99 | $208.15 |
| Indicator | BBY | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 66.87 |
| Support Level | N/A | $194.77 |
| Resistance Level | $67.51 | N/A |
| Average True Range (ATR) | 1.86 | 5.01 |
| MACD | -0.53 | 0.38 |
| Stochastic Oscillator | 7.55 | 99.95 |
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.